Summary
Boston Scientific Corporation (BSX) filed an 8-K report detailing the outcomes of its 2025 Annual Meeting of Stockholders, held on May 1, 2025. The meeting confirmed strong shareholder support for the company's leadership and governance. All ten director nominees were overwhelmingly elected for a one-year term, indicating continued confidence in the current board's direction and oversight. Furthermore, the stockholders provided advisory approval for the compensation of the Named Executive Officers and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year 2025. A stockholder proposal supporting a simple majority vote was also approved on an advisory basis, suggesting a shareholder preference for a more straightforward voting mechanism.
Key Highlights
- 1All 10 director nominees were re-elected to the Board of Directors with substantial majority support.
- 2Shareholders provided advisory approval for the compensation of the Company’s Named Executive Officers.
- 3Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year 2025.
- 4A stockholder proposal titled 'Support Simple Majority Vote' was approved on an advisory basis.
- 5The Annual Meeting was held virtually via live webcast.
- 6There were significant 'Broker Non-Votes' reported across most resolutions, particularly for director elections and executive compensation.